MaxCyte Reports Financial Results for 2024
ROCKVILLE, MD – MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering technologies, has released its financial performance for the year 2024. The company has experienced a significant year, underscoring its capability to advance the development of next-generation cell therapeutics and technologies. Notably, the commitment to its core business orientation and strategic initiatives helped shape this year's outcomes and future directives.
Fourth Quarter Highlights
During the fourth quarter of 2024, MaxCyte posted a total revenue of $8.7 million. This represents a 45% decline compared to the same period in 2023 due to several one-time approval milestones from the prior year. However, the core business revenue alone reached $8.6 million, indicating a 20% increase year-over-year, showcasing the resilience of MaxCyte’s fundamental operations.
Annual Financial Results
For the complete fiscal year, total revenue amounted to $38.6 million, down from $41.3 million in 2023. This decline of 6% was moderated by a growth in core business revenue, which rose to $32.5 million, a commendable increase of 9%. Despite encountering challenges in SPL Program-related revenue that dipped to $6.1 million, the overall performance reflects the enduring strength and demand for MaxCyte’s cell engineering solutions.
Strategic Developments and Initiatives
Addressing the financial outcomes, Maher Masoud, President and CEO of MaxCyte, expressed satisfaction with the results, highlighting that the scaling of strategic partnerships, including a record six SPLs in 2024, has bolstered the company’s pipeline. With the introduction of TG Therapeutics to the SPL framework in early 2025, the future looks promising as MaxCyte continues to position itself as a leading provider in cell engineering.
Investment and Cash Position
MaxCyte concluded the year with a robust cash position of $190.3 million, equipping it to navigate future growth opportunities and potential challenges. This financial strength will enable strategic investments that underpin its market position and operational efficiency. As part of its forward-looking approach, the company has set issuance targets that include revenue growth expectations for core operations of between 8% to 15%, factoring in revenue generated from recent acquisitions.
Key Financial Metrics
Analyzing key metrics can provide insight into MaxCyte's operational efficacy:
- Installed base of instruments sold or licensed: 760
- Percentage of core revenue generated by SPL clients: 55%
- Number of active SPLs: 28
- Active clinical programs: 18
- Commercial programs under SPLs: 1
Looking Ahead to 2025
For the upcoming year, MaxCyte has provided clear guidance on its expectations. The company anticipates revenue growth for its core business, setting a range of 8% to 15% compared to its 2024 figures. Additionally, SPL program-related revenue is expected to rebound through disciplined investment strategies, with projected revenues nearing $5 million for the year.
Annual Growth Strategy
The financial results not only highlight prior successes but also set the stage for a robust growth trajectory. As MaxCyte evolves, the strategy focuses on enhancing operational efficiencies, expanding market share, and leveraging its core technology platforms to deliver value to shareholders while improving patient outcomes.
Frequently Asked Questions
What are MaxCyte's financial results for 2024?
MaxCyte reported total revenues of $38.6 million for 2024, with a notable 9% increase in core business revenue.
How did the fourth quarter perform compared to last year?
The fourth quarter revenues were $8.7 million, down 45% from the previous year's due to one-time milestones, although core business revenue grew 20% to $8.6 million.
What future growth does MaxCyte anticipate for 2025?
MaxCyte expects core business revenue to grow by 8% to 15%, with SPL-related revenue anticipated to reach approximately $5 million.
What strategic partnerships were formed in 2024?
In 2024, MaxCyte formed a record six Strategic Platform Licenses (SPLs), demonstrating its commitment to expanding collaborations in the biopharma sector.
What is MaxCyte's current cash position?
The company ended 2024 with $190.3 million in cash, cash equivalents, and investments, providing a strong financial foundation for future growth initiatives.
